on Nyxoah SA. (isin : BE0974358906)
Nyxoah Reports First Quarter 2025 Financial and Operating Results
Nyxoah SA has released its financial and operating results for the first quarter of 2025, with the company anticipating FDA Pre-Market Approval (PMA) for their Genio® system in the second quarter. Key financial figures show a revenue of €1.1 million, a slight decrease from €1.2 million in the same period of 2024. The operating loss widened from €12.2 million to €20.6 million, attributed to higher R&D expenses and increased selling, general, and administrative costs.
The company completed FDA validation requirements, with the final site inspection in progress. Cash and equivalents stood at €63.0 million, down from €85.6 million at 2024 end. An FDA Approvable Letter was received, marking the Genio® system's application as meeting significant regulatory standards. Nyxoah is confident in meeting the remaining criteria soon.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Nyxoah SA. news